What Is ARA-290? Benefits, Research & Safety

The development of ARA-290 arose from pioneering research into the non-haematopoietic tissue-protective functions of erythropoietin, led by Professor Anthony Cerami and Dr. Michael Brines at the Kenneth S. Warren Institute and subsequently Araim Pharmaceuticals. In the early 2000s, research demonstrated that EPO possessed potent tissue-protective properties independent of its well-known role in stimulating red blood cell production. Studies showed that EPO could protect neurons, cardiomyocytes, and other tissues from ischaemic, toxic, and inflammatory damage. However, the clinical application of EPO for tissue protection was severely limited by its haematopoietic effects — chronic EPO administration increased haematocrit, blood viscosity, and thromboembolic risk. Brines and Cerami identified that EPO's tissue-protective effects were mediated through a distinct receptor complex — the innate repair receptor (IRR) — rather than the classical homodimeric EPO receptor responsible for erythropoiesis. This discovery opened the possibility of designing molecules that selectively activated the IRR without stimulating red blood cell production. Through systematic structure–activity studies, the team identified the specific regions of the EPO molecule responsible for IRR binding and engineered a minimal peptide — ARA-290 — that retained tissue-protective activity whilst lacking erythropoietic stimulation. The 11-amino-acid sequence was optimised for receptor binding, stability, and manufacturability. ARA-290 entered clinical trials in the 2010s, with studies in sarcoidosis, diabetic neuropathy, and other neuropathic conditions. Results demonstrated meaningful improvements in small fibre nerve density and neuropathic symptoms, representing a novel therapeutic approach to conditions with limited treatment options.